rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

FOCL · Nasdaq

Health CareMedical DevicesNot moving yet

FOCL stood above a rising 150-day average in 41 of the last 52 weekly readings, and has been out of that trend for the last 9 weeks. It is 8.2% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 9
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$1.2M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
37 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$1.1MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months9
Sale orders, 12 months0
Buyers · sellers8 · 0
WhoDidSharesTraded
Steven AnnenSVP, Marketing & Product Mgmt.bought5,000at $4.7514 Aug 2026filed 17 Aug 2026
Sanket ShahGeneral Counsel & Corp Secbought5,000at $4.7514 Aug 2026filed 17 Aug 2026
Ryan RhodesChief Executive Officerbought21,000at $4.7514 Aug 2026filed 17 Aug 2026
Lance WillseyDirectorbought50,000at $4.7514 Aug 2026filed 17 Aug 2026
Kenneth S. MobeckChief Financial Officerbought5,000at $4.7514 Aug 2026filed 17 Aug 2026
Joshua LevineDirectorbought10,000at $4.7514 Aug 2026filed 17 Aug 2026
Fran SchulzDirectorbought10,000at $4.7514 Aug 2026filed 17 Aug 2026
David R. HornDirectorbought10,000at $4.7514 Aug 2026filed 17 Aug 2026
Joshua LevineDirectorbought10,000at $4.2211 May 2026filed 13 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders37+4 on the quarter
New · exited6 · 3
Reported value$75.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Soleus Capital Management, L.P.unchanged · filed 11 Aug 20267,309,254$37.9M00.0%
MORGAN STANLEYreduced · filed 13 Aug 20263,336,872$17.3M-8,408−0.3%
Rock Springs Capital Management LPadded · filed 14 Aug 20261,386,000$7.2M+8,000+0.6%
FLAX POND CAPITAL, LLCadded · filed 13 Aug 2026789,446$2.9M+6,000+0.8%
Bruce & Co., Inc.unchanged · filed 14 Aug 2026438,652$2.3M00.0%
Parkman Healthcare Partners LLCunchanged · filed 14 Aug 2026154,832$802K00.0%
ESSEX INVESTMENT MANAGEMENT CO LLCnew · filed 6 Aug 2026146,005$756K+146,005
CAHILL FINANCIAL ADVISORS INCunchanged · filed 11 Aug 2026134,960$699K00.0%
US BANCORP \DE\added · filed 12 Aug 2026122,500$635K+3,500+2.9%
UBS Group AGreduced · filed 13 Aug 2026118,395$613K-51,235−30.2%
31 Mar 2023 – 30 Jun 2026
324149Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

David R. Horn Company insiderDirector · last 14 Aug 20261 · 0
Fran Schulz Company insiderDirector · last 14 Aug 20261 · 0
Joshua Levine Company insiderDirector · last 14 Aug 20262 · 0
Kenneth S. Mobeck Company insiderChief Financial Officer · last 14 Aug 20261 · 0
Lance Willsey Company insiderDirector · last 14 Aug 20261 · 0
Ryan Rhodes Company insiderChief Executive Officer · last 14 Aug 20261 · 0
Sanket Shah Company insiderGeneral Counsel & Corp Sec · last 14 Aug 20261 · 0
Steven Annen Company insiderSVP, Marketing & Product Mgmt. · last 14 Aug 20261 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202542.5%
Operating profit marginFY 2025 · to 31 Dec 2025-35.0%
Return on capital employedFY 2025 · to 31 Dec 2025-59.0%
Debt to equityFY 2025 · to 31 Dec 20251.04×
Research spendFY 2025 · to 31 Dec 202513.7%
Share count trendFY 2025 · to 25 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$20.5M

Analyst forecasts

No analyst forecasts yet.